Pancrelipase delayed-release capsules - AbbVie
Alternative Names: CREON; Lipacreon; SA-001Latest Information Update: 05 Nov 2023
At a glance
- Originator Solvay Pharmaceuticals
- Developer Abbott Laboratories; AbbVie; Eisai Co Ltd
- Class Pancreatic enzymes
- Mechanism of Action Pancrelipase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Exocrine pancreatic insufficiency
- No development reported Short bowel syndrome
Most Recent Events
- 08 Sep 2021 Discontinued - Phase-III for Exocrine pancreatic insufficiency (In children, In infants) in Russia (PO)
- 08 Sep 2021 No development reported - Phase-II for Short bowel syndrome (In adolescents, In children, In adults) in USA (PO)
- 01 Feb 2019 Children's Hospital of Philadelphia and AbbVie completes a phase II trial in Short bowel syndrome (In children, In adolescents, In adults) in USA (NCT03097029)